Efficacy and Safety of Eluxadoline in Patients With Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Irritable bowel syndrome with diarrhea (IBS-D) is a functional gastrointestinal disorder with limited effective treatment options. We evaluated the efficacy and safety of eluxadoline in patients with IBS-D who reported inadequate symptom control with prior loperamide. METHODS: Three hundred forty-six adults with IBS-D (Rome III criteria) were randomly assigned to placebo or eluxadoline 100 mg twice daily for 12 weeks. Patients recorded daily IBS-D symptoms, including worst abdominal pain (WAP) and stool consistency (through Bristol Stool Scale). The primary endpoint was proportion of composite responders, defined as patients who met daily composite response criteria (≥40% WAP improvement and <5 Bristol Stool Scale score) for at least 50% of treatment days, and recorded ≥60 days of diary entries over the 12-week period. RESULTS: Over 12 weeks, a significantly greater proportion of eluxadoline patients achieved the primary composite responder endpoint compared to placebo (22.7% vs 10.3%, P = 0.002), and component endpoints of improvements in stool consistency (27.9% vs 16.7%, P = 0.01) and WAP (43.6% vs 31.0%, P = 0.02). Additionally, a greater proportion of eluxadoline patients met the composite responder endpoint assessed at monthly intervals compared to placebo (weeks 1–4: 14.0% vs 6.9%, P = 0.03; weeks 5–8: 26.7% vs 14.9%, P = 0.006; weeks 9–12: 30.8% vs 16.7%, P = 0.002). Rates of adverse events were comparable in both groups (37.4% vs 35.3%); no treatment-related serious adverse event, cases of sphincter of Oddi spasm, or pancreatitis were reported. DISCUSSION: Eluxadoline appears safe and effective for treating IBS-D symptoms in patients with an intact gallbladder reporting inadequate relief with prior loperamide use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis
Lovell, R. M., & Ford, A. C. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.02.029 · Cited by 2,155
American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome
Ford, A. C., Moayyedi, P., Chey, W. D., Harris, L. A., Lacy, B. E., Saito, Y. A., & Quigley, E. M. M. (2018) · American Journal of Gastroenterology · doi:10.1038/s41395-018-0084-x · Cited by 388 · cited 1×
“strongly recommending against it as an IBS therapy (6).”
Eluxadoline for Irritable Bowel Syndrome with Diarrhea
Lembo, A. J., Lacy, B. E., Zuckerman, M. J., Schey, R., Dove, L. S., Andrae, D. A., Davenport, J. M., McIntyre, G., Lopez, R., Turner, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505180 · Cited by 334 · cited 2×
“In the two phase 3 studies (IBS-3001 [52-week treatment] and IBS-3002 [26-week treatment]) evaluating the safety and efficacy of eluxadoline, the primary composite endpoint was defined as a concurrent $30% improvement in daily abdominal pain score compared with baseline and a BSS score ,5 on at least 50% of days withi…”
BackgroundMayer, E. A. (2008) · New England Journal of Medicine · doi:10.1056/nejmcp0801447 · Cited by 243
Cited by
ACG Clinical Guideline: Management of Irritable Bowel Syndrome
Lacy, B. E., Pimentel, M., Brenner, D. M., Chey, W. D., Keefer, L. A., Long, M. D., & Moshiree, B. (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001036 · Cited by 893
Self-citationSavarino, E., Zingone, F., Barberio, B., Marasco, G., Akyuz, F., Akpinar, H., Barboi, O., Bodini, G., Bor, S., Chiarioni, G., et al. (2022) · United European Gastroenterology Journal · doi:10.1002/ueg2.12259 · Cited by 146
Brenner, D. M., & Sayuk, G. S. (2020) · Advances in Therapy · doi:10.1007/s12325-019-01116-z · Cited by 55
Self-citationAn evidence-based update on the diagnosis and management of irritable bowel syndrome
Black, C. J., & Ford, A. C. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2455586 · Cited by 27
“Eluxadoline has also been shown to be significantly more efficacious than placebo in a cohort of patients with IBS-D who reported inadequate symptom relief with loperamide [96].”
Metadata
- Authors
- Brenner, D. M., Sayuk, G. S., Gutman, C. R., Jo, E., Elmes, S. J. R., Liu, L. W. C., & Cash, B. D.
- Venue
- American Journal of Gastroenterology
- Published
- 2019-07-26
- Volume
- 114
- Issue
- 9
- Pages
- 1502-1511
- ISSN
- 0002-9270 (ISSN-L)
- 1572-0241
- OpenAlex
- W2964979565
- Cited by
- 54
- References
- 4
- FWCI
- 6.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of Eluxadoline in Patients With Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study. https://app.cochat.ai/papers/10.14309/ajg.0000000000000327
- The paper
- Brenner, D. M., Sayuk, G. S., Gutman, C. R., Jo, E., Elmes, S. J. R., Liu, L. W. C., & Cash, B. D. (2019). Efficacy and Safety of Eluxadoline in Patients With Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study. American Journal of Gastroenterology. https://doi.org/10.14309/ajg.0000000000000327
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.